Publications

Found 31 results

Sort by: Author Title Type [ Year  (Desc)]
Submitted
Njuru SN, Njogu PM, Mugo HN, Thoithi GN. "Is tablet splitting a potential pitfall in drug therapy? A case study of amlodipine tablets." Pharmaceut. Jour. Kenya. Submitted.
Degu A, Mekonnen A, Njogu P. "Treatment outcome among prostate cancer patients in Africa: A systematic review." Cancer Investigation. Submitted.
2022
2021
Amare GG, Degu A, Njogu P, Kifle ZD. "Evaluation of the antimalarial activity of the leaf latex of Aloe weloensis (Aloaceae) against plasmodium parasites." Evid-based Complem. Altern. Med. 2021;2021:6664711.
Mwangi AN, Njogu PM, Maru SM, Njuguna NM, Njaria PM, Mathenge AW. "Meloxicam emulgels for topical management of rheumatic diseases: Formulation development, in vitro and in vivo characterization." Saudi Pharmaceut. Jour. 2021;29(4):351-360.
2020
Kimondo J, Mutai P, Njogu P, Kimwele C. "Anti-inflammatory activity of selected plants used by the Ilkisonko Maasai, Kenya." Afr. J. Therapeut. Pharmacol. 2020;9(2):39-43.
Kabue KG, Njogu PM, Mwangi AN. "Exploring different approaches to improve the success of drug discovery and development projects." Futur. J. Pharm. Sci. 2020;6:27.
Mwangi M, Tirop L, Njogu P, Bururia J, Mwaura N, Mbae E. "Formulation of dispersible isoniazid/pyridoxine fixed-dose combination tablets for isoniazid-preventive therapy in paediatrics." Cogent Med. 2020;7(1):1787684.
Abuga KO, Ndwigah SN, Amugune BK, Ongarora DB, Njogu PM, Okaru AO, Kibwage IO. "Quality control report of drugs analyzed in the Drug Analysis and Research Unit during the period 2011-2015." East Cent. Afr. J. Pharm. Sci. 2020;23(3):79-86.
2019
2018
2017
Kawaljit S, Okombo J, Brunschwig C, Ndubi F, Barnard L, Wilkson C, Njogu PM, Njoroge M, et al. "Antimalarial pyrido[1,2-a]benzimidazoles: Lead optimization, parasite life cycle stage profile, mechanistic evaluation, killing kinetics and in vivo oral efficacy in a mouse model." J. Med. Chem. 2017;60(4):1432-1448.
Okombo J, Singh K, Ndubi F, Barnard L, Wilkson C, Peter M. Njogu, Mireille V, Keiser Jennifer, Egan T, Chibale K. "Antischistosomal activity of pyrido[1,2-a]benzimidazole derivatives and correlation with inhibition of β-hematin formation." ACS Infect. Dis.. 2017;3:411-420.
Degu A, Njogu P, Weru I, Karimi P. "Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya." Gynecol. Oncol. Res. Pract. 2017;4(15):1-15.
Njogu PM, Okombo J, Chibale K. "Designed Hybrid Compounds for Tropical Parasitic Diseases.". In: Design of Hybrid Molecules for Drug Development (First Edition). London: Elsevier; 2017.
2016
Njogu PM, Chibale K. "Current and Future Strategies for Improving Drug Discovery Efficiency.". In: Attrition in the Pharmaceutical Industry: Reasons, Implications and Pathways Forward. Hoboken: John Wiley & Sons, Inc; 2016.
Ngumo PM, Abuga KO, Njogu PM, Ongarora DSB. "A stability indicating liquid chromatography method for the assay of rufinamide bulk material and tablets." East Cent. Afr. J. Pharm. Sci . 2016;19:16-21.
2015
Kimondo J, Miaron J, Mutai P, Njogu P. "Ethnobotanical survey of food and medicinal plants of the Ilkisonko Maasai community in Kenya." Journal of Ethnopharmacology. 2015;175 :463-469.
Minyeto D, Njogu PM, Ndwigah SN, Chepkwony HK. "Quality and in vitro pharmaceutical equivalence of ciprofloxacin hydrochloride tablets brands in Kenya." East Cent. Afr. J. Pharm. Sci. 2015;18:75-85.2015_minyeto_et_al.pdf
2014
Mungai NN, Kibwage IO, Mwangi JW, Guantai AN, Njogu PM, Ongarora DSB. "Isolation, characterization and antiplasmodial activity of phytochemical constituents from Monanthotaxis parvifolia (Oliv.) Verdc ssp. kenyensis Verdc." East Cent. Afr. J. Pharm. Sci . 2014;17(3):87-93.
2013
Njogu PM, Gut J, Rosenthal PJ, Chibale K. "Design, synthesis and antiplasmodial activity of hybrid compounds based on (2R,3S)-N-benzoyl-3-phenylisoserine." ACS Med. Chem. Lett.. 2013;4(7):637-641. Abstract

A series of hybrid compounds based on (2R,3S)-N-benzoyl-3-phenylisoserine, artemisinin and quinoline moieties was synthesized and tested for in vitro antiplasmodial activity against erythrocytic stages of K1 and W2 strains of Plasmodium falciparum. Two hybrid compounds incorporating (2R,3S)-N-benzoyl-3-phenylisoserine and artemisinin scaffolds were three- to four-fold more active than dihydroartemisinin, with nanomolar IC50 values against Plasmodium falciparum K1 strain.

Njogu PM, Chibale K. "Recent Developments in Rationally Designed Multitarget Antiprotozoan Agents." Curr. Med. Chem. 2013;20(13):1715-1742. Abstract

Protozoan infections are the leading causes of morbidity and mortality among parasitic infections of humans, accounting for approximately 800 thousand mortalities and a loss of more than 30 million disability-adjusted life years annually. The major protozoan infections of humans, namely malaria, Chagas disease, human African trypanosomiasis, and leishmaniasis, are primarily centered in the tropics, with a reach into some subtropical regions of the world. Though globally massive in their impact, these diseases mostly afflict the least economically endowed and geographically marginalized populations in low-income countries. As such, there is no sufficient market incentive for industrial business-driven antiprotozoal drug discovery due to poor marketing prospects and low returns on investment. Consequently, the pharmacopoeia for majority of these diseases, composed mainly of agents with poor efficacy and unsatisfactory safety profiles, has essentially remained unchanged for decades, creating a compelling need for more efficacious and better tolerated medicines. The policy makers and the scientific community are seeking effective ways to meet this need. So far, two approaches have emerged promising in this regard: combination chemotherapy and drug repositioning. Molecular hybridization has been cited as a potential third approach that could be used to deliver new antiprotozoal chemical entities. In this review article, recent applications of this novel strategy in antimalarial, antichagasic, antitrypanosomal, and antileishmanial drug discovery research and development over the last five years will be presented and discussed.

2012
Njogu PM, Hendricks DT, Chibale K. "Hybrids of (2R,3S)-N-benzoyl-3-phenylisoserine and anticancer pharmacophores: Design, synthesis and biological evaluation.". In: 12th Frank Warren Conference 2012. Bloemfontein, South Africa; 2012.
2011
Njogu PM, Thoithi GN, Mwangi JW, Kamau FN, Kibwage IO, Kariuki ST, Yenesew A, Mugo HN, Mwalukumbi JM. "Phytochemical and Antimicrobial Investigation of Girardinia diversifolia (Link) Friis (Urticaceae)." East Cent. Afr. J. Pharm. Sci. 2011;14(3):89-94. AbstractPhytochemical and Antimicrobial Investigation of Girardinia diversifolia (Link) Friis (Urticaceae)

Root and stem extracts of Girardinia diversifolia exhibited varying degrees of activity against Bacillus pumilus, Staphylococcus aureus, Escherichia coli, Aspergillus niger, Candida albicans and Saccharomyces cerevisiae. Three compounds namely β-sitosterol, 7-hydroxysitosterol and 3-hydroxystigmast-5-en-7-one, were isolated from the petroleum ether root extract. The present study gives scientific credence to the traditional use of Girardinia diversifolia in the management of microbial infections.

UoN Websites Search